[3]Peter Robert Galle, Thomas Decaens, Masatoshi Kudo, et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): F...
1.Peter Robert Galle, et al.Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW. J Clin Oncol 4...
CheckMate 9DW研究 在Ⅲ期CheckMate 9DW研究(NCT04039607)中,与仑伐替尼(LEN)/索拉非尼(SOR)相比,一线纳武利尤单抗(NIVO)+伊匹木单抗(IPI)在未接受治疗的uHCC患者中显示出显著的总生存期(OS)获益和更高的客观缓解率(ORR),并且缓解持久,安全性可控。本次大会报告了按最佳总缓解(BOR)亚组和基线特征划分的疗效,...
CheckMate 9DW的首次结果显示,尼武单抗联合易普利木单抗与乐伐替尼或索拉非尼作为一线治疗不可切除肝细胞癌.pptx,Nivolumab plus ipilimumab vs lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma: first results from CheckMat
9 RegisterLog in Sign up with one click: Facebook Twitter Google Share on Facebook CHM (redirected fromcheckmate) Dictionary Thesaurus Medical Legal Financial Encyclopedia Wikipedia Related to checkmate:chess Category filter: AcronymDefinition CHMChemistry ...
然而,最近的联合试验,包括CheckMate 9LA[10]和针对间皮瘤的CheckMate 743[19],采用了固定剂量的纳武利尤单抗,每2周240 mg,或者每3周360 mg。药代动力学数据表明,与基于体重的给药剂量相比,固定剂量的ICIs产生的药物暴露与之相似[15],但关于患者结局(如毒性和疗效)的数据较少。
In the phase 3 CheckMate 9DW study, 1L NIVO + IPI demonstrated statistically significant and clinically meaningful overall survival (OS) benefit vs LEN/SOR in patients (pts) with uHCC (NCT04039607). We present additional exploratory analyses from this preplanned interim analysis. Methods Pts with...
We report first results from the preplanned interim analysis of the phase 3, open-label, randomized CheckMate 9DW trial evaluating the efficacy and safety of NIVO + IPI vs LEN or SOR as first-line therapy for pts with uHCC (NCT04039607).Methods:Adult pts with previously untreated HCC not ...
CheckMate 9DW是一项开放标签、随机、III期研究,纳入标准为既往未经治疗的且不适合外科治疗的晚期肝细胞癌(HCC)患者。患者随机(1:1)分配接受纳武利尤单抗联合伊匹木单抗治疗最多4个周期,序贯至多2年的纳武利尤单抗单药治疗(试验组,n=335)或接受研究者选择的仑伐替尼或索拉非尼治疗(对照组,n=333),直至疾病进展或...
秦教授认为,CheckMate-9DW研究报道的阳性结果是本次ASCO大会的重要亮点,也具有非常重要的临床意义。 主要终点mOS长达23.7个月,2年OS率高达49%,双免疫治疗“拖尾效应”突出 在研究主要终点方面,O+Y组较对照组可显著改善患者OS(mOS 23.7 vs. 20.6月,HR 0.79,p=0.018),2年OS率49% vs. 39%(图2)。